Design Therapeutics (DSGN) Stock Price, News & Analysis

Company Overview

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Key Stats

• Today's Range: $13.96 to $14.68
• 50-Day Range: $9.99 to $15.79
• 52-Week Range: $3.11 to $17.25
• Volume: 394,077 shs
• Average Volume: 540,056 shs
• Market Capitalization: $880.69 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $16.50
• Consensus Rating: Moderate Buy

Design Therapeutics Stock Analysis - MarketRank™

Design Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 571st out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Design Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Design Therapeutics has a consensus price target of $16.50, representing about 17.0% upside from its current price of $14.10.

Amount of Analyst Coverage

Design Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Design Therapeutics are expected to decrease in the coming year, from ($1.39) to ($1.70) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Design Therapeutics is -11.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Design Therapeutics is -11.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Design Therapeutics has a P/B Ratio of 4.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.74% of the float of Design Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Design Therapeutics has a short interest ratio ("days to cover") of 6.81.

Change versus previous month

Short interest in Design Therapeutics has recently increased by 7.60%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Design Therapeutics does not currently pay a dividend.

Dividend Growth

Design Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.27

News Sentiment

Design Therapeutics has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Design Therapeutics this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Design Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

23.50% of the stock of Design Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

56.64% of the stock of Design Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DSGN Stock Analysis - Frequently Asked Questions

How have DSGN shares performed this year?

Design Therapeutics' stock was trading at $9.38 at the beginning of 2026. Since then, DSGN stock has increased by 50.3% and is now trading at $14.10.

How were Design Therapeutics' earnings last quarter?

Design Therapeutics, Inc. (NASDAQ:DSGN) issued its quarterly earnings data on Tuesday, April, 28th. The company reported ($0.29) EPS for the quarter, beating analysts' consensus estimates of ($0.36) by $0.07.
Read the conference call transcript.

When did Design Therapeutics IPO?

Design Therapeutics (DSGN) raised $228 million in an initial public offering on Friday, March 26th 2021. The company issued 12,000,000 shares at a price of $18.00-$20.00 per share. Goldman Sachs, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

Who are Design Therapeutics' major shareholders?

Design Therapeutics' top institutional investors include Dimensional Fund Advisors LP (0.69%), Bank of New York Mellon Corp (0.13%), Strs Ohio (0.07%) and AlphaCentric Advisors LLC (0.03%). Insiders that own company stock include Rodney W Lappe, John P Schmid, Deepa Prasad and Arsani William.
View institutional ownership trends.

How do I buy shares of Design Therapeutics?

Shares of DSGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Design Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Design Therapeutics investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

• Last Earnings: 4/28/2026
• Today: 5/08/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DSGN
• CIK: 1807120
• Web: www.designtx.com
• Phone: 858-293-4900
• Fax: N/A
• Employees: 40
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Design Therapeutics: $16.50
• High Price Target: $21.00
• Low Price Target: $14.00
• Potential Upside/Downside: +17.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$69.79 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -33.07%
• Return on Assets: -31.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 22.28
• Quick Ratio: 22.28

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.49 per share
• Price / Book: 4.04

Miscellaneous

• Outstanding Shares: 62,460,000
• Free Float: 47,780,000
• Market Cap: $880.69 million
• Optionable: Optionable
• Beta: 1.73